New pill aims to stop prediabetes in its tracks

NCT ID NCT07286747

Recruiting now Prevention Sponsor: University Hospital Schleswig-Holstein Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This study tests whether a new form of nicotinic acid (vitamin B3), designed to release in the lower gut, can help people with prediabetes return to normal blood sugar levels and avoid type 2 diabetes. About 390 adults with prediabetes will take either the drug or a placebo daily for 26 weeks, along with lifestyle advice. The main goal is to see if the drug can safely reverse prediabetes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES (INSULIN RESISTANCE, IMPAIRED GLUCOSE TOLERANCE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University Medical Center Schleswig-Holstein, Campus Kiel
RECRUITING

Kiel, 24105, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Leipzig Medical Center
RECRUITING

Leipzig, 04103, Germany

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PREDIABETES (INSULIN RESISTANCE, IMPAIRED GLUCOSE TOLERANCE) PREDIABETES (INSULIN RESISTANCE, IMPAIRED GLUCOSE TOLERANCE)